iRadimed (NASDAQ:IRMD) CFO Sells $1,459,350.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CFO John Glenn sold 15,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares in the company, valued at approximately $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

iRadimed Price Performance

Shares of iRadimed stock opened at $96.23 on Monday. The firm has a 50 day simple moving average of $84.16 and a 200 day simple moving average of $71.74. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $98.44. The firm has a market cap of $1.22 billion, a P/E ratio of 58.32 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The firm had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, sell-side analysts expect that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The company also recently disclosed a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be issued a dividend of $0.50 per share. The ex-dividend date is Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on IRMD shares. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research upgraded iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Wednesday. Lake Street Capital restated a “buy” rating and issued a $100.00 price target on shares of iRadimed in a research note on Monday, November 3rd. Finally, Roth Capital set a $90.00 price target on shares of iRadimed in a research report on Friday, October 31st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

Institutional Trading of iRadimed

Institutional investors have recently modified their holdings of the stock. CWM LLC raised its stake in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 211 shares in the last quarter. Quarry LP acquired a new stake in shares of iRadimed during the 3rd quarter worth approximately $40,000. Tower Research Capital LLC TRC increased its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the last quarter. State of Alaska Department of Revenue bought a new position in iRadimed in the third quarter valued at approximately $47,000. Finally, Spire Wealth Management bought a new stake in iRadimed during the second quarter worth $60,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.